Allogene Therapeutics
Judy Seng is an experienced professional in clinical operations, currently serving as Associate Director of Clinical Operations at Allogene Therapeutics, where expertise in overseeing clinical trials and operations is utilized. Prior to this role, Judy held the position of Associate Clinical Trial Specialist at Medtronic, contributing to the successful management and execution of clinical studies.
This person is not in any teams
This person is not in any offices
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.